Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while GraniteShares 2x Long NVDA Daily ETF trades at $33.53 (market cap $3.52B). The key difference: GraniteShares 2x Long NVDA Daily ETF is far larger — about 3.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and GraniteShares 2x Long NVDA Daily ETF is more actively traded (6,205,788 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and GraniteShares 2x Long NVDA Daily ETF for 15 Days on average.
| MRVI | NVDL | |
|---|---|---|
Market Cap | $972.90M | $3.52B |
Volume | 4,325,710 | 6,205,788 |
Sector | Health | Leveraged / Inverse |
52-Week High | $9.00 | $43.02 |
52-Week Low | $2.83 | $21.76 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.58 with a 1.81% daily gain. Technical indicators show a bullish overall signal with mixed moving averages and neutral oscillators. The ETF tracks Nvidia's performance with 2x daily leverage, though recent articles highlight it underperformed NVDA's 22.21% one-year return with only 17.21%. Recent news focuses on Nvidia's strong earnings and AI leadership driving optimism.
The outlook remains tied to Nvidia's AI dominance and earnings momentum, offering leveraged exposure to chip sector growth. Key risks include leverage decay, tracking error, and Nvidia's high valuation sensitivity. Investors should weigh the ETF's daily reset mechanism against long-term holding costs amid volatile tech markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
